Showing 1231-1240 of 1716 results for "".
Should Children and Adolescents Be Screened for Primary Hyperhidrosis?
https://practicaldermatology.com/issues/novemberdecember-2025/should-children-and-adolescents-be-screened-for-primary-hyperhidrosis/48891/Primary hyperhidrosis (PH) is a chronic, often underreported and underdiagnosed condition without a cure. While it frequently runs in families, the exact etiology is unknown.Can Prescription Hyperhidrosis Treatments Help Mitigate Symptoms?
https://practicaldermatology.com/issues/novemberdecember-2025/can-prescription-hyperhidrosis-treatments-help-mitigate-symptoms/48890/Clinicians should begin to think beyond standard protocols and recognize sweat management as a potentially powerful tool in their therapeutic arsenal.Can Prescription Hyperhidrosis Treatments Help Mitigate Symptoms?
https://practicaldermatology.com/topics/rare-disease/can-prescription-hyperhidrosis-treatments-help-mitigate-symptoms/39997/Should Children and Adolescents Be Screened for Primary Hyperhidrosis?
https://practicaldermatology.com/topics/rare-disease/should-children-and-adolescents-be-screened-for-primary-hyperhidrosis/39946/Cutaneous Manifestations Associated with Nemolizumab
https://practicaldermatology.com/issues/september-2025/cutaneous-manifestations-associated-with-nemolizumab/37628/In the 2025 study by Sasaki et al entitled “Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: a multicenter retrospective study in Japan,” nemolizumab-induced cutaneous eruptions were found to be relatively common, typically occuPreparing for Private Equity: Benefits and Drawbacks
https://practicaldermatology.com/issues/september-2025/preparing-for-private-equity-benefits-and-drawbacks/37629/Over the past decade, the health care industry has emerged as a prime target for private equity (PE) investment.The Benefits of Private Practice: A Q&A with Joel Schlessinger, MD, FAAD
https://practicaldermatology.com/issues/september-2025/the-benefits-of-private-practice-a-qa-with-joel-schlessinger-md-faad/37630/While selling to and working for private equity–backed platforms may have its perks, many long-time private practitioners warn that the advantages of private practice are often not fully appreciated until it is too late. Practical Dermatology Chief Cosmetic Surgery Editor Emeritus Joel Schlessinger,Dermatology Recruitment in the Age of Private Equity
https://practicaldermatology.com/issues/september-2025/dermatology-recruitment-in-the-age-of-private-equity/37638/A recruiting executive offers a balanced view from the fieldFirst Reported Case of Red Face Response to Tralokinumab in the United States
https://practicaldermatology.com/issues/september-2025/first-reported-case-of-red-face-response-to-tralokinumab-in-the-united-states/37639/The chronic nature of atopic dermatitis (AD), which currently affects approximately 10.8% of children and 7.3% of adults in the United States,1 makes long-term management challenging.The ESOP Model: An Alternative to PE for Dermatology Practices
https://practicaldermatology.com/issues/september-2025/the-esop-model-an-alternative-to-pe-for-dermatology-practices/37637/Not all practice models are as simple as private practice vs private equity. At Ada West Dermatology in Boise, Idaho, we’ve adopted a somewhat uncommon business model called an employee stock ownership plan (ESOP) and it’s worked very well for us.